drugset / Trial / NCT02175342
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
RandomizedParallel-groupDouble-blindTreatment
Summary
This pharmacodynamic and pharmacokinetic dose-ranging study aims to determine the optimal dose of tiotropium inhaled as a solution from a Respimat device once a day for three weeks in patients with COPD.
Timeline
- Start
- 1998-03-01
- Primary completion
- 1999-04-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tiotropium | Other / unclassified | 0.625 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 1.25 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 2.5 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 5 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 10 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |